StockData
Autolus Therapeutics plc logo

Autolus Therapeutics plc (AUTL) stock

AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3019% below fair value
$1.14−0.03 (-2.56%)

Close on Nov 16, 2026Market cap $303.43MP/E –Yield –

Autolus Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Autolus Therapeutics's enterprise value was $127.06M on Nov 11, 2026, against $7.86M a year earlier. Over the last 5 years it ranged from -$229.67M to $869.41M, with a median of $20.93M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$127.06M-21.7%
2025Dec 31, 2025$162.23M–
2024Dec 31, 2024-$111.65M-114.8%
2023Dec 29, 2023$755.56M–
2022Dec 30, 2022-$26.09M-158.1%
2021Dec 31, 2021$44.88M-57.0%
2020Dec 31, 2020$104.42M-38.6%
2019Dec 31, 2019$169.95M-78.5%
2018Dec 31, 2018$789.73M–

More Autolus Therapeutics figures

See a number that looks wrong?